CATX
HealthcarePerspective Therapeutics, Inc.
$2.73
$-0.06 (-2.15%)
Jan 5, 2026
Price History (1Y)
Analysis
Perspective Therapeutics, Inc. is a healthcare company in the medical devices industry with a market capitalization of $202.94M and approximately 138 employees. The company's revenue for the trailing twelve months (TTM) was $1.07M. The company's financial health is marked by significant losses, with a net income of -$106.31M TTM, EBITDA of -$91.69M, and free cash flow of -$79.28M. The gross margin, operating margin, and profit margin are all 0.0%, indicating no profitability. The return on equity (ROE) is -37.3%, and the return on assets (ROA) is -17.2%. The debt to equity ratio is 1.37, while cash stands at $174.14M with a debt of $3.31M. The company's valuation metrics include a price to book ratio of 0.84 and a price to sales ratio of 188.78. The forward P/E ratio is -2.02, which indicates significant losses in the near future. Revenue growth has been negative at -43.4% year-over-year (YoY), while earnings growth is not available due to the loss reported by the company.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Visit website →Key Statistics
- Market Cap
- $202.94M
- P/E Ratio
- N/A
- 52-Week High
- $5.39
- 52-Week Low
- $1.60
- Avg Volume
- 1.70M
- Beta
- 1.19
Company Info
- Industry
- Medical Devices
- Exchange
- ASE
- Country
- United States
- Employees
- 138